News & Updates

The multi-targeted tyrosine-kinase inhibitor (TKI) ponatinib appears to be active against a subset of cancers characterized by the presence of cells positive for alternative lengthening of telomeres (ALT), a team of Singapore-based investigators has found.

Couples infected with SARS-CoV-2 while receiving assisted reproductive technology (ART) treatment had lower quality embryo and blastocyst rates compared with uninfected couples in a  multicentre cohort study.

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Individuals who use proton pump inhibitors (PPIs) appear to be at heightened risk of pneumonia, as reported in a study.

For older people, administering metformin before or during a period of reduced physical activity appears to have potential benefits for the muscles, such as reducing atrophy and improving recovery, as reported by a team of US-based researchers.

Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.